ReviewFrontiers in nutrition2021
Gut Microbiota Is a Potential Biomarker in Inflammatory Bowel Disease.
Review in Frontiers in nutrition, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Debate on the relationship betweenFrontiers in microbiology · 2024Pooled it
- Human biomarker navigator.iMeta · 2026Review
- How Complex Dietary Fibers Can Be Used to Shape the Human Gut Microbiome Toward Reduced Inflammatory Potential: A Pilot Study.Molecules (Basel, Switzerland) · 2026Article
- Fecal calprotectin and gut microbiome in a cohort without intestinal pathologies from northern Italy.iScience · 2026Article
- Impact of Fermented Dairy on Gastrointestinal Health and Associated Biomarkers.Nutrition reviews · 2026Review
- Diet in Inflammatory Bowel Diseases: Efficacy, Tolerability, and Microbiome Effects Toward Personalized Management.Digestive diseases and sciences · 2026Review
- Cross-ethnic evaluation of gut microbial signatures reveal increased colonization with oral pathobionts in the north Indian inflammatory bowel disease cohort.Intestinal research · 2026Article
- Oral delivery of engineeredMaterials today. Bio · 2026Article
- Immunoproteomic insights into inflammatory diseases of the critically endangered black rhinoceros (Diceros bicornis).Scientific reports · 2026Article
- Gut Microbiota Alterations and Dysbiosis Patterns in Pediatric Inflammatory Bowel Disease: Clinical Correlations and Therapeutic Impact.Journal of clinical medicine · 2026Article
- Gut microbiota and uveitis: exploring novel mechanisms of inflammatory ocular diseases via the gut-eye axis.Frontiers in microbiology · 2026Review
- Platelet-Rich Plasma Attenuates Knee Osteoarthritis in Rats via Modulation of Gut Microbiota.Drug design, development and therapy · 2026Article
- Geniposide Alleviates Inflammatory Bowel Disease by Regulating Intestinal Flora and Arginine Metabolism and Inhibiting the NF-κB Pathway Through Targeting Anxa5.Mediators of inflammation · 2026Article
- Pre-treatment serum extracellular vesicle-enriched microbiome profiles and SSRI treatment response in obsessive-compulsive disorder: a prospective naturalistic cohort study.Frontiers in psychiatry · 2026Article
- Deciphering gut microbial impact in coronary artery disease through multimodal computational approaches.BMC microbiology · 2025Article
- Associations of the intestinal microbiota with plasma bile acids and inflammation markers in Crohn's disease and ulcerative colitis.Scientific reports · 2025Article
- Fermented pickles improve gut microbiota and immune profile in women in a community trial in rural Pakistan.Scientific reports · 2025Article
- Dynamics of tissue and fecal microbiota in active Crohn's disease and their ability to predict disease state.World journal of gastrointestinal pathophysiology · 2025Article
- A multicellular self-organized probiotic platform for oral delivery enhances intestinal colonization.Nature communications · 2025Article
- Galectin-3-Insights from Inflammatory Bowel Disease and Primary Sclerosing Cholangitis.International journal of molecular sciences · 2025Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is characterized by relapse and remission alternately. It remains a great challenge to diagnose and assess disease activity during IBD due to the lack of specific markers. While traditional biomarkers from plasma and stool, such as C-reactive protein (CRP), fecal calprotectin (FC), and S100A12, can be used to measure inflammation, they are not specific to IBD and difficult to determine an effective cut-off value. There is consensus that gut microbiota is crucial for intestinal dysbiosis is closely associated with IBD etiopathology and pathogenesis. Multiple studies have documented differences in the composition of gut microbiota between patients with IBD and healthy individuals, particularly regarding microbial diversity and relative abundance of specific bacteria. Patients with IBD have higher levels of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.